Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study.
(2022) Acta Oncologica — Vol. 61, n° 11, p. 1332-1338 (2022)
Files
2022_Le_Calvez_Acta_Oncol.pdf
Open Access - Adobe PDF
- 1.23 MB
Details
- Authors
Le Calvez, Baptiste 
Le Bourgeois, Amandine
- Abstract
- BACKGROUND: Despite therapeutic progress, 10 to 30% of adult patients with primary mediastinal B cell lymphoma (PMBCL) are primary refractory or experience early relapse (R/R). Allogeneic stem cell transplantation (allo-HSCT) thus remains a potentially curative option in this setting. MATERIAL AND METHODS: In this multicenter retrospective study, the outcomes of 33 French and Belgian adult patients allo-transplanted for R/R PMBCL between January 1999 and December 2018, were examined. RESULTS: At allo-HSCT time, patients had received a median of 3 treatment lines, 50% of them were in complete response, 40% in partial response and 10% had a progressive disease. Forty-two percent of the donors were siblings and 39% matched related. The median follow-up for alive patients was 78 months (3.5-157). Considering the whole cohort, 2-year overall survival (OS), progression free survival (PFS) and graft-versus-host disease-free/relapse-free survival (GRFS) were 48% (95%CI: 33-70), 47% (95%CI: 33-68) and 38.5% (95%CI: 25-60) respectively. Cumulative incidence of relapse and non-relapse mortality rates were respectively 34% (95%CI: 18-50) and 18% (95%CI: 7-34). Disease status at transplant was the only factor predicting survivals, patients with progressive disease showing significant lower 2-year PFS (HR: 6.12, 95%CI: 1.32-28.31, p = 0.02) and OS (HR: 7.04, 95%CI: 1.52-32.75, p = 0.013). A plateau was observed for OS and PFS after 4 years with 10 patients alive after this date, suggesting that almost one third of the patients effectively salvaged and undergoing allo-SCT could be cured. CONCLUSION: This study indicates that allo-HSCT is a valid therapeutic option for R/R PMBCL, providing durable remissions.
- Affiliations
Citations
Le Calvez, B., Tessoullin, B., Renaud, L., Botella-Garcia, C., Srour, M., Le Gouill, S., Guillerm, G., Gressin, R., Nguyen Quoc, S., Furst, S., Chauchet, A., Sibon, D., Lewalle, P., Poire, X., Maillard, N., Villate, A., Loschi, M., Paillassa, J., Beguin, Y., et al. (2022). Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study. Acta Oncologica, 61(11), 1332-1338. https://doi.org/10.1080/0284186X.2022.2130709 (Original work published 2022)